Durable Responses With PD-1 Inhibition in Lung and Kidney Cancer and the Ongoing Search for Predictive Biomarkers
- 20 June 2015
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (18) , 1993-1994
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- Effects of MAPK and PI3K Pathways on PD-L1 Expression in MelanomaClinical Cancer Research, 2014
- Targeted therapy for renal cell carcinoma: The next lapJournal of Carcinogenesis, 2014
- Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung TumorsCancer Discovery, 2013
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in MelanomaNew England Journal of Medicine, 2013
- Nivolumab plus Ipilimumab in Advanced MelanomaNew England Journal of Medicine, 2013
- Mutational heterogeneity in cancer and the search for new cancer-associated genesNature, 2013
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Meta-Analysis of Randomized Controlled Trials for the Incidence and Risk of Treatment-Related Mortality in Patients With Cancer Treated With Vascular Endothelial Growth Factor Tyrosine Kinase InhibitorsJournal of Clinical Oncology, 2012
- Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With ChemotherapyJournal of Clinical Oncology, 2004